A phase I/II trial of Cabazitaxel +/- Rhenium-188 HEDP in patients with metastatic castration resistant prostate cancer who progressed on or after a docetaxel containing treatment.

Trial Profile

A phase I/II trial of Cabazitaxel +/- Rhenium-188 HEDP in patients with metastatic castration resistant prostate cancer who progressed on or after a docetaxel containing treatment.

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 07 Jun 2016

At a glance

  • Drugs Cabazitaxel (Primary) ; Rhenium-188-etidronic acid
  • Indications Prostate cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ReCab study
  • Most Recent Events

    • 13 Oct 2012 New source identified and integrated (European Clinical Trials Database; EudraCT2011-005116-28).
    • 13 Oct 2012 Status changed from planning to recruiting as reported by European Clinical Trials Database.
    • 01 Feb 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top